pemvidutide
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 27, 2023 (NCT05989711)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glucagon receptorAGONIST
GCGR agonist
GLP1R agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095142 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07009860 | Phase 2 | Jun 16, 2025 | Altimmune, Inc. |
| NCT06987513 | Phase 2 | May 15, 2025 | Altimmune, Inc. |
| NCT05989711 | Phase 2 | Jul 27, 2023 | Altimmune, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Altimmune, Inc. | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1